Cabozantinib significantly improves progression free survival in patients with advanced neuroendocrine tumors
1. In this randomized controlled trial, cabozantinib significantly improved progression-free survival in patients with progressive pancreatic and extra-pancreatic neuroendocrine tumors. ...